These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 23786843)

  • 81. [Effectiveness of the correction of hepatotoxicity during combined chemoradiotherapy for cancer patients].
    Korytova LI; Meshechkin AV; Zhabina RM; Masliukova EA; Sokurenko VP
    Vopr Onkol; 2013; 59(4):518-20. PubMed ID: 24032231
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Oral chemotherapeutic agents for colorectal cancer.
    Sharma S; Saltz LB
    Oncologist; 2000; 5(2):99-107. PubMed ID: 10794800
    [TBL] [Abstract][Full Text] [Related]  

  • 83. The 2001 European Cancer Conference. Lisbon, Portugal. October 21-25, 2001.
    Fisher MD; D'Orazio AI
    Clin Colorectal Cancer; 2002 Feb; 1(4):203-7. PubMed ID: 12450418
    [No Abstract]   [Full Text] [Related]  

  • 84. Dynamic Changes with Liver Atrophy as an Alternate Marker of Chemotherapy-Associated Liver Injury.
    Wakai T; Prasoon P
    Ann Surg Oncol; 2019 Nov; 26(12):3813-3814. PubMed ID: 31429021
    [No Abstract]   [Full Text] [Related]  

  • 85. Third-line treatment strategies in metastatic colorectal cancer.
    Prager GW
    Clin Adv Hematol Oncol; 2021 Dec; 19 Suppl 24(12):2-6. PubMed ID: 35289796
    [No Abstract]   [Full Text] [Related]  

  • 86. Optimizing administration of third-line treatment in metastatic colorectal cancer: Q&A.
    Prager GW; Argilés G
    Clin Adv Hematol Oncol; 2021 Dec; 19 Suppl 24(12):16-17. PubMed ID: 35289799
    [No Abstract]   [Full Text] [Related]  

  • 87. Proactive transitioning to third-line treatment in metastatic colorectal cancer.
    Bekaii-Saab TS
    Clin Adv Hematol Oncol; 2021 Jan; 19 Suppl 3(1):5-7. PubMed ID: 33843900
    [No Abstract]   [Full Text] [Related]  

  • 88. The importance of exposing patients with metastatic colorectal cancer to all treatment options.
    Loupakis F
    Clin Adv Hematol Oncol; 2021 Jan; 19 Suppl 3(1):3-5. PubMed ID: 33843899
    [No Abstract]   [Full Text] [Related]  

  • 89. Turmeric supplement induced hepatotoxicity: a rare complication of a poorly regulated substance.
    Suhail FK; Masood U; Sharma A; John S; Dhamoon A
    Clin Toxicol (Phila); 2020 Mar; 58(3):216-217. PubMed ID: 31271321
    [No Abstract]   [Full Text] [Related]  

  • 90. Hepatotoxicity of chemotherapy.
    Sachs B; Haider S; Balaraman R; Shahab N; Perry MC
    Expert Opin Drug Saf; 2002 Nov; 1(4):339-53. PubMed ID: 12904134
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Front-Line Treatment of Metastatic Colorectal Cancer.
    Sama AR; Cohen SJ
    J Oncol Pract; 2016 Dec; 12(12):1231-1233. PubMed ID: 27943685
    [No Abstract]   [Full Text] [Related]  

  • 92. Response to "Loss of Muscle Mass During Chemotherapy Is Predictive for Poor Survival of Patients With Metastatic Colorectal Cancer".
    Daly LE; Ryan AM; Power DG
    J Clin Oncol; 2016 Nov; 34(31):3816-3817. PubMed ID: 27480154
    [No Abstract]   [Full Text] [Related]  

  • 93. Chemotherapeutic agents and hepatotoxicity.
    Perry MC
    Semin Oncol; 1992 Oct; 19(5):551-65. PubMed ID: 1411653
    [No Abstract]   [Full Text] [Related]  

  • 94. Irinotecan-Induced Steatohepatitis: Current Insights.
    Han J; Zhang J; Zhang C
    Front Oncol; 2021; 11():754891. PubMed ID: 34707997
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Single-cell landscape of malignant ascites from patients with metastatic colorectal cancer.
    Zhou H; Yin J; Wang A; Yin X; Jin T; Xu K; Zhu L; Wang J; Wang W; Zhang W; Li X; Hu Z; Li X
    Cancer Commun (Lond); 2024 Jul; 44(7):713-717. PubMed ID: 38532531
    [No Abstract]   [Full Text] [Related]  

  • 96. Hepatotoxicity Secondary to Chemotherapy.
    Grigorian A; O'Brien CB
    J Clin Transl Hepatol; 2014 Jun; 2(2):95-102. PubMed ID: 26357620
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Management of hepatotoxicity of chemotherapy and targeted agents.
    Mudd TW; Guddati AK
    Am J Cancer Res; 2021; 11(7):3461-3474. PubMed ID: 34354855
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Uncommon Adverse Effects of Commonly Used Chemotherapeutic Agents in Medical Oncology Practice: A Series of Two Cases of Hand-Foot Syndrome.
    Dar W; Hussain M; Aziz SA; Mohammad G; Wani B; Latief M
    Indian J Med Paediatr Oncol; 2017; 38(3):380-382. PubMed ID: 29200697
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Chemotherapy-associated hepatotoxicity in colorectal cancer.
    Cai Z; Yang J; Shu X; Xiong X
    J BUON; 2014; 19(2):350-6. PubMed ID: 24965391
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Advancements in colorectal cancer research: Unveiling the cellular and molecular mechanisms of neddylation (Review).
    Wang T; Li X; Ma R; Sun J; Huang S; Sun Z; Wang M
    Int J Oncol; 2024 Apr; 64(4):. PubMed ID: 38391033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.